SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Attention centers on Alpha Taus clinical pipeline, particularly reported early REGAIN results in recurrent glioblastoma and the FDA-cleared trial expansion, alongside completed enrollment in its pancreatic cancer IMPACT study and further data milestones ahead. Traders are largely bullish on the catalysts, though some note share-price resistance and volatility; the early clinical signals remain preliminary.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

The FDA issued a Complete Response Letter for Summits ivonescimab application, saying the PFS benefit did not support approval without statistically significant overall-survival evidence. Traders are reacting with sharp bearish concern, while some holders argue the setback is limited to this indication and point to the HARMONi-3 readout and broader pipeline as remaining catalysts.

Helus Pharma, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Helus Pharma is drawing attention ahead of the Phase 3 APPROACH topline readout for HLP003 in major depressive disorder, a pivotal clinical catalyst for the company. Traders are optimistic about its potential and adjunctive design, while others emphasize the binary efficacy risk and concerns about dilution and competition.

The Home Depot, Inc. engages in the sale of building materials and home improvement products. Its products include building materials, home improvement products, lawn and garden products and décor products. The firm operates through the following geographical segments: U.S., Canada and Mexico. It offers home improvement installation services, and tool and rental equipment. The company was founded by Bernard Marcus, Arthur M. Blank, Kenneth Gerald Langone and Pat Farrah on June 29, 1978 and is headquartered at Atlanta, GA.

Home Depot, Inc.

Home Depots upcoming Q3 report is the main focus, with traders weighing the stocks recent rally against concerns that high rates and sluggish housing are weighing on home-project demand. Some see continued momentum and resilient consumer spending, while others view the earnings report as a risk given signs of softer spending.

Delta Air Lines, Inc. engages in the provision of scheduled air transportation for passengers and cargo. It operates through the Airline and Refinery segments. The Airline segment provides scheduled air transportation for passengers and cargo. The Refinery segment provides jet fuel to the airline segment. The company was founded by Collett Everman Woolman in 1928 and is headquartered in Atlanta, GA.

Delta Air Lines, Inc.

A nationwide FAA ground stop following an air-traffic-control communications outage is driving concern about Deltas flight disruptions and potential costs, even though the restriction has been lifted and recovery delays remain. Traders debate whether the hit will be brief or weigh on results, while speculation about cyberattacks or deliberate causes is not confirmed.

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,112,050. The last known price of Bitcoin is 63,437.21016941 USD and is down -7.02 over the last 24 hours. It is currently trading on 12780 active market(s) with $45,086,253,428.50 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

Bitcoins sharp selloff and volatile rebound are driving discussion, with traders split over whether support in the low-$60,000s marks a bottom or another leg lower; many describe the move as liquidation-driven. Community explanations also point to ETF selling, the Binance hack and rate concerns, while others expect an oversold bounce.

Cardano (ADA) is a cryptocurrency launched in 2017. Cardano has a current supply of 44,994,648,344.194204 with 36,816,370,531.313927 in circulation. The last known price of Cardano is 0.14666837 USD and is down -12.66 over the last 24 hours. It is currently trading on 1753 active market(s) with $480,085,527.58 traded over the last 24 hours. More information can be found at https://www.cardano.org.

Cardano

Cardanos steep decline amid broader crypto weakness is driving bearish chatter, compounded by traders interpreting Hoskinsons comments that the roadmap is complete as a sign the project may be abandoned. Some holders counter that the networks infrastructure is finished and point to ongoing ecosystem development, while others are buying the dip or watching for a reversal.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Disneys upcoming quarterly results are the main focus, with traders weighing streaming profitability and parks performance against softer Asia parks and recent movie misses. Some expect earnings to support the stock, while others are cautious about its stalled move near resistance.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

Promising early CTX310 and zugo-cel clinical updates are drawing attention, but traders are divided as the shares have struggled to respond: bulls see pipeline validation alongside growing CASGEVY uptake, while skeptics point to small datasets, long development timelines and persistent weak price action.

HawKeye 360, Inc. engages in the provision of defense technology. It offers spectrum monitoring, maritime intelligence, air defence radar monitoring, GNSS interference detection, and communications mapping. Its costumers include a wide range of commercial, government and international entities. The company was founded by Charles T. Clancy, Robert G. McGwier, Chris DeMay and John Serafini in 2015 and is headquartered in Herndon, VA.

HawkEye 360 Inc.

HawkEye 360s record third-quarter results and raised full-year outlook are driving attention, with traders pointing to strong growth and defense demand behind the sharp rally. The reaction is largely bullish, though some note the company remains loss-making and question whether the gains can hold.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Rocket Lab CEO Says It Could Be ‘Extremely Profitable’ Without Neutron — But SpaceX Is Not The Only Reason It’s Building The Rocket

Equity

Even if SpaceX launches for less, Beck wants to reserve half of Neutron’s capacity over time for Rocket Lab’s own missions.

RKLB Vs. SPCX: Which Space Stock Has More Upside As Rocket Lab’s Iridium Deal Deepens Spectrum Feud?

SpaceX says Rocket Lab’s $8 billion Iridium takeover could give its spectrum rival more power to obstruct competitors.

RKLB Stock Sinks After-Hours On Q3 Earnings Miss, But Neutron Launches Now Fetch $70M – And New Buyers Face A 2030s Wait 

Longer term, Rocket Lab wants half of Neutron’s capacity for its own services and sees potential Neutron non-GAAP gross margins above 50%.

RKLB Stock Climbs Overnight Ahead Of Earnings — Bulls Bet Neutron Delay Is Priced In Amid Fresh Progress 

Rocket Lab completed construction and curing of Neutron’s first-stage forward dome.

RKLB’s Iridium Deal Draws Heat As Globalstar Echoes SpaceX Concerns — Rocket Lab Seeks Fast FCC Approval 

Globalstar warned that Rocket Lab’s supplier relationship could give it an incentive to favor Iridium at Globalstar’s expense.

RKLB Stock Rises Overnight Despite CFO’s $7.7M Sale Plan — This Analyst Sticks To $90 Target Even Amid Neutron Setback

Citizens expects Neutron’s debut in late fiscal second-quarter 2027 but says the delay leaves its investment case intact.

Stocktwits Space Race Monthly: SPCX Holds Up Better Than ASTS, RKLB And PL In October — But VSAT Takes The Crown 

Viasat drew Amazon takeover speculation, while advancing NASA work and satellite-connectivity partnerships.

RKLB Stock Tests Bulls’ Patience — Rocket Lab’s NASA Robot Eyes Repairs As Neutron Advances, 100th Electron Ships 

Neutron’s second stage and thrust module reached Virginia ahead of ground testing.

SPCX, ASTS, RKLB Slide Overnight: Amazon Reaffirms 2026 Satellite Service Debut — Retail Weighs Competitive Threat 

Amazon’s Globalstar deal and upcoming direct-to-device network increase potential competition with ASTS.

RKLB Stock Eyes Best Week In A Month: Neutron, Electron And NASA Updates Stack Up — Why Is Retail Still On The Fence?

Neutron’s second stage and thrust module reached Wallops Island for checks ahead of ground testing.

Tidal Trust II - Defiance Daily Target 2X Long RKLB ETF

Bearish Sentiment

<ul class="summary-bullets"><li>Beck said Rocket Lab would be “extremely profitable” without Neutron, with space systems generating 80% of quarterly sales.</li><li>Neutron’s first 16 flights are booked, including eight worth roughly $515 million, with new slots available in the 2030s.</li><li>With Neutron taking priority, Beck is putting his own time and money into a mission to search Venus’s clouds for signs of life.</li></ul>Rocket Lab (RKLB) CEO Peter Beck said the company would be “extremely profitable” without Neutron, but he sees a reason to keep building it even if SpaceX wins on launch costs. Rocket Lab wants to fly its own satellites into a space services market he believes could reach $1 trillion.<a href="https://stocktwits.com/symbol/RKLB">RKLB stock</a> jumped over 5% on Wednesday to $66.15, with shares tracking their best week in over three months.&nbsp;<h2 class="st-heading-2">Why Rocket Lab Wants Its Own Ride To Orbit</h2>“It’s always about Neutron. And Neutron is the giant sucking sound of all cash and resources in the company,” Beck said in an&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.youtube.com/watch?v=UDZx8Pxk54A">interview</a> with The Angry Astronaut. “But you minus Neutron out and this company is an extremely profitable, great company.”&nbsp;Rocket Lab already earns most of its revenue from building spacecraft and components. Its space systems business generated $214.8 million in the third quarter, about 80% of the company’s $267.8 million in sales. Rocket Lab posted a net loss of $79.7 million for the quarter. Research and development spending rose 39% from a&nbsp; year ago to $98.4 million, partly due to Neutron.&nbsp;When asked how Neutron would compete if SpaceX makes Starship fully reusable, Beck raised a question about who would get to fly on it. He pointed to Falcon 9, where launch priorities can shift to accommodate SpaceX’s own missions.“That also assumes that, that SpaceX make the Starship available for everybody else. And, you know, I’m sure Elon’s first priority is SpaceX and not everybody else,” Beck said.Owning Neutron would give Rocket Lab control over when its own satellites fly. On Monday’s earnings call, Beck said customers would get most of the early flights as Rocket Lab fulfills its contracts. In the longer term, he expects to reserve about half of Neutron’s launch capacity for the company’s own missions.“When I say 50% for us and 50% for everybody else, that is not out of the chute, obviously,” Beck said. “We will burn down a whole bunch of contracted launch, so that number will skew to our customers really heavily for quite some time.”<h2 class="st-heading-2">RKLB CEO Sees $1 Trillion Market Beyond Launch</h2>Beck put the launch market at $10 billion to $20 billion. He sees a far bigger opportunity in the services Rocket Lab could sell once its satellites are in orbit. “The total addressable market in services from space is $350 billion going to $1 trillion,” he said in the interview.Rocket Lab’s proposed $8 billion acquisition of Iridium Communications (IRDM) would give it an operating satellite network and an established customer base. On Monday’s earnings call, Beck said Neutron could eventually launch replacements for Iridium’s satellites. Iridium shareholders have approved the deal, which the companies expect to close in mid-2027.When asked in the interview where Rocket Lab could be in five years, Beck said its ambitions extend beyond Iridium. The plan, dating back to when Rocket Lab went public, was to build spacecraft, launch them and ultimately sell services from orbit. “No, we’ll continue to keep growing into more and more space services and keep on adding more and more to the portfolio,” he said.<h2 class="st-heading-2">Neutron’s 2027 Debut Takes Priority Over Venus Mission&nbsp;</h2>Neutron’s first 16 flights are booked, and the next customer slots are in the 2030s, Beck told analysts Monday. Eight missions signed in the third quarter were worth $515 million, including several at a higher base price of $70 million per launch.The debut slipped to 2027 after engineers found gaps in the forward dome of Neutron’s first-stage propellant tank. Rocket Lab has built a replacement, but the tank still needs assembly and testing. Beck said that the carbon-composite design should eventually make tanks lighter and cheaper to build. He expects the first flight to succeed, even if engineers need flight data to understand how well Neutron can be reused.The push has left little time for a probe waiting in a Long Beach clean room. Beck wants to send it into the clouds of Venus to look for signs of life. With no clear financial return for shareholders, he is putting his own time and money into the mission.“So and as I’m sure you can appreciate, Neutron is consuming any night and any weekend of any person in this company,” Beck said. “So it doesn’t get a lot of love, but, but it is a mission that’s dear to me.”<h2 class="st-heading-2">How Do Retail Traders Feel About RKLB?</h2>On Stocktwits, retail sentiment for RKLB slipped to ‘bullish’ from ‘extremely bullish’ levels a day ago amid ‘high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/rklb_ss_fdcc806563.png" alt="rklb ss.png" width="643" height="338"><figcaption>RKLB sentiment and message volume as of November 11 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/TheBando/message/668858520">said</a>, “$RKLB buy the stock now get stuck in the 50 to $60 range until neutron shoots off which is anyone's guess, at least 6 months I would imagine.”<stembedurl>https://stocktwits.com/TheBando/message/668858520</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/Hegemon/message/668743882">said</a>, “$RKLB yeah there's gonna be a crazy pre neutron run. That delay was a gift from impatients to patients.”<stembedurl>https://stocktwits.com/Hegemon/message/668743882</stembedurl>RKLB stock has declined 5% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tsla-stock-climbs-after-elon-musk-extends-cybertruck-run-through-summer-2027-citing-sentimentality/cNGDx6dR992">TSLA Stock Gains After Elon Musk Extends Cybertruck Run Despite Profit Trade-Off, Citing ‘Sentimentality’&nbsp;</a>

Rocket Lab CEO Peter Beck speaks during the opening of the new Rocket Lab factory on October 12, 2018 in Auckland, New Zealand. (Photo by Phil Walter/Getty Images)

Tema Space Innovators ETF

Rocket Lab USA Inc

Defiance Daily Target 2X Long RKLB ETF

Leverage Shares 2x Long SPCX Daily ETF

Defiance Daily 2X Space ETF

Tradr 2X Long SpaceX Daily ETF

SpaceX

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$11.50
Prev Close	$12.51
Open	$12.44
Dividend Yield	N/A
50-Day Moving Average	$13.62
Beta	N/A
Avg. Volume	3.29M
PE Ratio	N/A

52-Week High	$114.83
52-Week Low	$6.02
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

RKLX Fundamentals